Parthenolide repressed endometriosis induced surgically in rats: Role of PTEN/PI3Kinase/AKT/GSK-3β/β-catenin signaling in inhibition of epithelial mesenchymal transition
article
OA: closed
CC0
⤵ 1 in-corpus citation
AI-generated summary
Parthenolide repressed surgically induced endometriosis in rats by inhibiting epithelial-mesenchymal transition through the PTEN/PI3K/AKT/GSK-3β/β-catenin signaling pathway.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
AIM: PI3K/AKT/GSK-3β/β-catenin signaling pathway is a triggering factor for epithelial to mesenchymal transition (EMT) which plays a pivotal role in the pathogenesis of endometriosis. Parthenolide is a sesquiterpene lactone extract that has anti-inflammatory, analgesic and anticancer properties. Hence, we investigated the effect of parthenolide against EMT in the endometrial tissue implants and immortalized epithelial endometriotic cell lines 12Z.
MAIN METHODS: Twenty- four female Rats with surgically induced endometriosis were treated with parthenolide (2, 4 mg/kg), for 4 weeks. Endometriotic cell line 12Z was used to identify the effect of parthenolide on the wound healing, cellular migration and invasion properties of endometriotic cells.
KEY FINDINGS: Parthenolide decreased the endometriotic implant tissue expression of total PI3K, PI3K-p85, p-AKT, p/total AKT, p-GSK-3β, P/total GSK-3β, and nβ-catenin, as well as increased E-cadherin and decreased vimentin mRNA expression. Parthenolide upregulated PTEN immunoreactivity as well as the endometriotic tissue caspase-3, caspase-9, BAX levels while reducing Bcl2 level. Additionally, parthenolide decreased endometriotic tissue implants surface area and histopathological score of the epithelial growth.
SIGNIFICANCE: Our findings showed that parthenolide in a dose dependent manner inhibited PI3K/AKT/GSK-3β/nβ-catenin cascade via enhancement of PTEN with subsequent inhibition of EMT evidenced by elevation of the epithelial marker, E-cadherin and reduction of mesenchymal marker, vimentin, of the endometriotic implants in addition to reversal of invasion and migration properties of epithelial endometriotic cell lines. These findings provide a valuable therapeutic approach for treatment of endometriosis.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (61)
- 17βE2 promotes cell proliferation in endometriosis by decreasing PTEN via NFκB-dependent pathway via openalex
- Ameliorative Effects of Quercetin and Metformin and Their Combination Against Experimental Endometriosis in Rats via openalex
- Angiogenesis and Endometriosis via openalex
- Apoptosis in human endometrium and endometriosis via openalex
- Atorvastatin causes regression of endometriotic implants in a rat model via openalex
- Daidzein-rich isoflavone aglycones inhibit cell growth and inflammation in endometriosis via openalex
- Endometriotic cells are resistant to interferon-γ-induced cell growth inhibition and apoptosis: a possible mechanism involved in the pathogenesis of endometriosis via openalex
- Epithelial-to-mesenchymal transition in the development of endometriosis via openalex
- Expression of selected tumor suppressor and oncogenes in endometrium of women with endometriosis via openalex
- Interleukin‐22 secreted by ectopic endometrial stromal cells and natural killer cells promotes the recruitment of macrophages through promoting CCL2 secretion via openalex
- In Vitro and In Vivo Effects of Tumor Suppressor Gene PTEN on Endometriosis: An Experimental Study via openalex
- In Vitro Effects of a Small-Molecule Antagonist of the Tcf/ß-Catenin Complex on Endometrial and Endometriotic Cells of Patients with Endometriosis via openalex
- In‑vitro models of human endometriosis (Review) via openalex
- PI3K/AKT pathway is altered in the endometriosis patient’s endometrium and presents differences according to severity stage via openalex
- Secreted frizzled-related protein 2 (SFRP2) expression promotes lesion proliferation via canonical WNT signaling and indicates lesion borders in extraovarian endometriosis via openalex
- Serial analysis of gene expression reveals differential expression between endometriosis and normal endometrium. Possible roles for AXL and SHC1 in the pathogenesis of endometriosis via openalex
- The Origin and Pathogenesis of Endometriosis via openalex
- Time to redefine endometriosis including its pro-fibrotic nature via openalex
- β-catenin signaling inhibitors ICG-001 and C-82 improve fibrosis in preclinical models of endometriosis via openalex
- W2606513998 via openalex
- W2612133931 via openalex
- W2618632515 via openalex
- W2751080201 via openalex
- W2766723766 via openalex
- W2781813834 via openalex
- W2798260604 via openalex
- W2803306454 via openalex
- W2808015032 via openalex
- W2909281294 via openalex
- W2938022022 via openalex
- W2962586713 via openalex
- W2969770152 via openalex
- W3124678786 via openalex
- W3167776014 via openalex
- W3177845102 via openalex
- W4281944024 via openalex
- W6642880528 via openalex
- W6675698577 via openalex
- W6680959544 via openalex
- W6747906291 via openalex
- W6769958332 via openalex
- W1968013406 via openalex
- W6771374719 via openalex
- W1971586374 via openalex
- W1994682335 via openalex
- W2021159269 via openalex
- W2037451324 via openalex
- W2064847453 via openalex
- W2070731236 via openalex
- W2072503088 via openalex
- W2078606646 via openalex
- W2084228958 via openalex
- W2092209895 via openalex
- W2099486836 via openalex
- W2106651240 via openalex
- W2126371827 via openalex
- W2140777557 via openalex
- W2148124890 via openalex
- W2172100996 via openalex
- W2339269407 via openalex
- W2584071154 via openalex
Cited by (1)
Source provenance
- europepmc
- last seen: 2026-09-19T06:15:14.566301+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-09-19T06:13:47.709341+00:00
License: CC0
· commercial use OK